Developing innovative oncology therapeutics that target multiple mechanisms of cancer growth and spread.

Gertrude Biomedical is a private, early-stage biotechnology company developing small molecule inhibitors to SOX18, a unique drug target with significant commercial and clinical potential.
The Gertrude Biomedical team combines expertise in SOX18 biology, medicinal chemistry, drug development and the clinical application.